In-hospital ( 43/153 [ 28.1 % ] vs 27/152 [ 17.8 % ] ; p = 0.037 ) and 3-month ( 46/153 [ 30.1 % ] vs 31/152 [ 20.4 % ] ; p = 0.036 ) mortality rates were significantly higher in talactoferrin-treated patients than in patients in the placebo group .